

JUL 14 2005 10:23AM

STEINBERG & RASKIN

JC04 Rec'd PCT/PTO 14 JUL 2005

NO. 534 P. 1/7

932.1271

**UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED  
CENTRAL FAX CENTER

JUL 14 2005

Re: Applicants: ARMENGOL ASPARO, Montserrat et al.

Serial No.: 10/509,918

Filing Date: October 4, 2004

Title: PROCESS FOR PREPARING A  
PHARMACEUTICALLY ACTIVE COMPOUND

**REQUEST FOR CORRECTED FILING RECEIPT**

**Via Facsimile (703) 746-9195**

March 29, 2005

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Attn: Office of Initial Patent Examination  
Customer Service Center

Dear Sir/Madam:

Applicant respectfully requests that a corrected filing receipt be issued in connection with the above-identified patent application. Specifically, as indicated in the enclosed marked-up copy of the filing receipt, the title of the application should be set forth as "PROCESS FOR PREPARING A PHARMACEUTICALLY ACTIVE COMPOUND" instead of as "PROCESS FOR PREPARING A RIZATRIPTAN".

It is respectfully advised that the title had been set forth as above in the Transmittal letter as filed with the application, and accordingly it is submitted that correction is appropriate. A copy of the Transmittal letter as filed is enclosed herewith for your reference.

I hereby certify that this correspondence is being  
facsimile transmitted to the U.S. Patent and  
Trademark Office on March 29, 2005.

STEINBERG & RASKIN, P.C.

By: 

G:\Network Files\93211271\prorecuio\Request for Corrected Filing Receipt.wpd

RECEIVED  
OPE/14P

JUL 14 2005

Serial No.: 10/509,918

It is respectfully requested that the correction be entered into the record and that a corrected filing receipt be forwarded to us at your earliest convenience.

Respectfully submitted,

STEINBERG & RASKIN, P.C.

By:



Dona C. Edwards

Reg. No. 42,507

STEINBERG & RASKIN, P.C.  
1140 Avenue of the Americas, 15th Floor  
New York, NY 10036-5803  
Telephone: (212) 768-3800  
Facsimile: (212) 382-2124  
E-mail: [pto@steinbergraskin.com](mailto:pto@steinbergraskin.com)

DCE:jc

Encls.

cc: Martin G. Raskin, Esq. (w/o encls.)

G:\Network File\9321271\prosecution\Request for Corrected Filing Receipt.wpd



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address COMMISSIONER FOR PATENTS  
P.O. Box 1459  
Alexandria, Virginia 22303-1459  
www.uspto.gov

APPL NO.	FILING OR 971 (e) DATE	ART UNIT	FIL FEE RECT	ATTY/DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/509,918	10/04/2004	1625	950	932.1271		13	1

21831

STEINBERG & RASKIN, P.C.  
1140 AVENUE OF THE AMERICAS, 15th FLOOR  
NEW YORK, NY 10036-5803

CONFIRMATION NO. 4465

## FILING RECEIPT



\*OC000000015472124\*

Date Mailed: 03/17/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Montserrat Armengol Asparo, Sant Joan Despi, SPAIN;  
Pere Dalmases Barjoan, Sant Feliu De Llobregat, SPAIN;

Power of Attorney: The patent practitioners associated with Customer Number 21831.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/IB03/03540 08/05/2003

## Foreign Applications

SPAIN P-200201874 08/07/2002

Projected Publication Date: 06/23/2005


Non-Publication Request: No

Early Publication Request: No

## Title

Process for preparing a ~~receptor~~

pharmaceutically active compound



BEST AVAILABLE COPY

Preliminary Class

548

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**BEST AVAILABLE COPY**

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): ARMENGOL ASPARO, Montserrat et al.

Docket No.

932.1271

Application No.

N/Y/K

Filing Date

October 4, 2004

Examiner

N/Y/K

Customer No.

21831

Group Art Unit

N/Y/K

Invention:

**PROCESS FOR PREPARING A PHARMACEUTICALLY ACTIVE COMPOUND**

I hereby certify that the following correspondence:

New PCT National Phase Application with associated documents and fee

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 4, 2004

(Date)

Annette McPherson

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)


EV 333148254 US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

FORM PTO-1190 (Modified) U.S. PATENT AND TRADEMARK OFFICE, U.S. DEPARTMENT OF COMMERCE (REV. 07-2004)		ATTORNEY'S DOCKET NUMBER 932.1271.
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
INTERNATIONAL APPLICATION NO. PCT/IB2003/003540	INTERNATIONAL FILING DATE August 5, 2000	PRIORITY DATE CLAIMED August 7, 2002
TITLE OF INVENTION PROCESS FOR PREPARING A PHARMACEUTICALLY ACTIVE COMPOUND		
APPLICANT(S) FOR DO/EO/US ARMENGOL ASPARO, Montserrat et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol> <p>Items 13 to 23 below concern document(s) or information included:</p> <ol style="list-style-type: none"> <li>13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Express Mail Label No. <u>EV 333148254 US</u></li> <li>23. <input checked="" type="checkbox"/> Other items or information: Letter Re Priority</li> </ol>		

BEST AVAILABLE COPY

U.S. APPLICATION NO (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. <b>PCT/IB2003/003540</b>		ATTORNEY'S DOCKET NUMBER <b>932.1271</b>	
24. The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)) :</b> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1110.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$950.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$790.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$750.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>RECEIVED</b> <b>CENTRAL FAX CENTER</b> <b>JUL 14 2005</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	13 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$88.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$930.00</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$0.00	
<b>SUBTOTAL =</b>				<b>\$930.00</b>	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00	
<b>TOTAL NATIONAL FEE =</b>				<b>\$930.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input checked="" type="checkbox"/>				\$40.00	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$970.00</b>	
				Amount to be:	\$
				refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$970.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-0518</u> d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
<b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
<b>SEND ALL CORRESPONDENCE TO:</b> <b>STEINBERG &amp; RASKIN, P.C.</b> 1140 Avenue of the Americas 15th Floor New York, NY 10036-5803					
 SIGNATURE <b>Dona C. Edwards</b> NAME <u>42,507</u> REGISTRATION NUMBER <u>October 4, 2004</u> DATE					